Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin Degludec vs Glargine in Critical Illness
NCT06178874Completed
- Sponsor
- Ain Shams University
- Start
- Dec 2023
- Primary completion
- May 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of insulin degludec in hyperglycemia (3 arms), sponsored by Ain Shams University. Primary endpoint: Hyperglycemic control at 10 days. Started Dec 2023; status: completed.
02
Drugs
insulin degludec
03
Conditions
hyperglycemia
Beyond the preview
Go deeper on NCT06178874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06178874.